The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines
Jieru Yang,
Jennifer C. Boer,
Mattaka Khongkow,
Sarunya Phunpee,
Zeinab G. Khalil,
Sahra Bashiri,
Cyril Deceneux,
Georgia Goodchild,
Waleed M. Hussein,
Robert J. Capon,
Uracha Ruktanonchai,
Magdalena Plebanski,
Istvan Toth,
Mariusz Skwarczynski
Affiliations
Jieru Yang
School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
Jennifer C. Boer
School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, VIC 3083, Australia
Mattaka Khongkow
National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), 111 Thailand Science Park, Phahonyothin Road, Klong 1, Pathumthani 12120, Thailand
Sarunya Phunpee
National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), 111 Thailand Science Park, Phahonyothin Road, Klong 1, Pathumthani 12120, Thailand
Zeinab G. Khalil
Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia
Sahra Bashiri
School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
Cyril Deceneux
School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, VIC 3083, Australia
Georgia Goodchild
School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, VIC 3083, Australia
Waleed M. Hussein
School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
Robert J. Capon
Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia
Uracha Ruktanonchai
National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), 111 Thailand Science Park, Phahonyothin Road, Klong 1, Pathumthani 12120, Thailand
Magdalena Plebanski
School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, VIC 3083, Australia
Istvan Toth
School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
Mariusz Skwarczynski
School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
Intranasal vaccine administration can overcome the disadvantages of injectable vaccines and present greater efficiency for mass immunization. However, the development of intranasal vaccines is challenged by poor mucosal immunogenicity of antigens and the limited availability of mucosal adjuvants. Here, we examined a number of self-adjuvanting liposomal systems for intranasal delivery of lipopeptide vaccine against group A Streptococcus (GAS). Among them, two liposome formulations bearing lipidated cell-penetrating peptide KALA and a new lipidated chitosan derivative (oleoyl-quaternized chitosan, OTMC) stimulated high systemic antibody titers in outbred mice. The antibodies were fully functional and were able to kill GAS bacteria. Importantly, OTMC was far more effective at stimulating antibody production than the classical immune-stimulating trimethyl chitosan formulation. In a simple physical mixture, OTMC also enhanced the immune responses of the tested vaccine, without the need for a liposome delivery system. The adjuvanting capacity of OTMC was further confirmed by its ability to stimulate cytokine production by dendritic cells. Thus, we discovered a new immune stimulant with promising properties for mucosal vaccine development.
